Pfizer/Lilly ready to ditch painful past with new tanezumab trials
This article was originally published in Scrip
After five years of waiting, Pfizer and Lilly are ready to restart late-stage clinical trials for the pain drug tanezumab, the big pharmas announced 23 March. The move forward scores Pfizer a $200m milestone payment and signals a jumpstart for the class of drugs.
You may also be interested in...
Larger of two doses of the NGF inhibitor hit two efficacy endpoints, but the rate of joint health outcomes on a composite measure was higher than control by a statistically significant margin.
Pfizer and Lilly said tanezumab reduced pain in a Phase III osteoarthritis study, but safety is the biggest question for NGF inhibitors. Yet, while Regeneron and Teva discontinued dosing for their fasinumab at its highest dose, tanezumab was effective at both doses in its first Phase III test.
Canada’s Antibe Therapeutics is accelerating the early-stage clinical development of new molecules that depend on the cytoprotective and signaling properties of minute amounts of hydrogen sulfide to have a potent anti-inflammatory and analgesic effect.